Literature DB >> 28719585

Immunotherapy: Reality check for nivolumab in advanced-stage melanoma.

Diana Romero.   

Abstract

Entities:  

Year:  2017        PMID： 28719585     DOI： 10.1038/nrclinonc.2017.112

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  2 in total

1.  Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.

Authors:  James Larkin; David Minor; Sandra D'Angelo; Bart Neyns; Michael Smylie; Wilson H Miller; Ralf Gutzmer; Gerald Linette; Bartosz Chmielowski; Christopher D Lao; Paul Lorigan; Kenneth Grossmann; Jessica C Hassel; Mario Sznol; Adil Daud; Jeffrey Sosman; Nikhil Khushalani; Dirk Schadendorf; Christoph Hoeller; Dana Walker; George Kong; Christine Horak; Jeffrey Weber
Journal:  J Clin Oncol       Date:  2017-07-03       Impact factor: 44.544

2.  Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials.

Authors:  Georgina V Long; Jeffrey S Weber; James Larkin; Victoria Atkinson; Jean-Jacques Grob; Dirk Schadendorf; Reinhard Dummer; Caroline Robert; Ivan Márquez-Rodas; Catriona McNeil; Henrik Schmidt; Karen Briscoe; Jean-François Baurain; F Stephen Hodi; Jedd D Wolchok
Journal:  JAMA Oncol       Date:  2017-11-01       Impact factor: 31.777
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.